Abstracts

Changes in Markers of T-Cell Senescence and Exhaustion With HIV Therapy

Residual immune activation and immunosenescence may contribute to chronic comorbidities in treated HIV-1 infection. It is unclear whether the integrase inhibitor, raltegravir (RAL), which has increased penetration into the gastrointestinal and lymphoid tissues, affects immunosenescence and T cell exhaustion to a greater extent than ritonavir boosted protease inhibitors (PIs). A5260s is a substudy of a…

Pharmacokinetics of Daily Nevirapine in Neonates at High Risk of HIV Acquisition

Infants born to HIV-infected women with no or a short duration of antiretroviral treatment during pregnancy are at high-risk of perinatal transmission. Nevirapine (NVP) is a key component of antiretroviral (ARV) prophylaxis for infants at high risk of intrapartum HIV infection.  We developed a population pharmacokinetic (PK) model to describe NVP concentrations in infants from…

TLR9 Variant Is Associated With Earlier HIV, EBV, and CMV Acquisition in Infants

Cytomegalovirus (CMV) and Epstein-Barr (EBV) virus are acquired by the majority of African HIV-infected infants during the first year of life. Both viruses establish persistent infection with prolonged systemic viremia. CMV is associated with an increased risk of HIV progression, morbidity, mortality and developmental impairment. EBV is an important contributor to lymphoma in the setting…

HCMV Induces CCR5 Expression, Activation and HIV Infection at Feto-Maternal Interface

Despite effective administration of combination antiretroviral therapy to HIV-1–infected pregnant women, mother-to-child transmission (MTCT) of HIV-1 remains a significant global public health concern. Co-pathogens that pose threats to the developing fetus include human cytomegalovirus (HCMV), may also facilitate in utero transmission of HIV-1 in populations where co-infection is common. HCMV infects up to 90% of…

Infant Cotrimoxazole Prophylaxis Associated With Commensal Bacterial Resistance

Cotrimoxazole (CTX) prophylaxis reduces morbidity and mortality in HIV-infected children, even in settings with high background rates of CTX-resistant pathogens. However, with declining mother-to-child HIV transmission globally, the risks and benefits of infant empiric CTX prophylaxis need to be re-evaluated, including the potential for higher rates of resistance to CTX and other antibiotics following CTX…